Novel Oral Anticoagulants (NOACs) are front line medications for the prevention of cerebrovascular accident secondary to cardio-embolism. Recently, NOACs are replacing coumarins since they do not require close monitoring. But, real world evidence was required to evaluate the extent of adherence to these agents. Accordingly, sub-optimal adherence to NOACs was noted based on evidence obtained from a meta-analysis of 1.6 million Atrial Fibrillation (AF) patients. Interventions should be promptly designed to improve the compliance of patients for NOACs. Further, the availability and affordability of these medications should be insured in developing countries to save the lives of individuals who are suffering from AF.
The finding of the study is available from the following link. doi: 10.2174/1570161116666180123111949.